• In recent days, Cardinal Health reported an 11% year-over-year revenue increase and raised its fiscal 2026 non-GAAP EPS guidance, supported by strong demand for higher-margin specialty drugs and operational improvements.
• This combination of upgraded profit expectations and growing specialty exposure has become a key focus for investors assessing the company’s earnings power ahead of its next results.
• Now we’ll examine how the raised earnings guidance, underpinned by specialty drug demand, affects Cardinal Health’s broader investment narrative and outlook.

Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

Cardinal Health Investment Narrative Recap

To own Cardinal Health today, you need to believe that its scale in pharmaceutical distribution and growing specialty exposure can support steadily improving earnings despite thin margins and regulatory pressure. The raised 2026 non GAAP EPS guidance, driven by higher margin specialty drugs and efficiency efforts, directly reinforces the near term earnings catalyst, while the biggest ongoing risk still comes from pricing scrutiny and potential reimbursement or policy changes that could compress those same margins.

Among recent announcements, the company’s decision to increase its quarterly dividend to US$0.5158 per share stands out alongside the upgraded earnings outlook. Together with ongoing share repurchases, this signals that management is allocating capital with an eye on shareholder returns as it leans into specialty growth and operational improvements that underpin its current earnings narrative.

Yet, even as profit guidance rises, investors should be aware of how shifts in government pricing and reimbursement policies could...

Cardinal Health's narrative projects $314.4 billion revenue and $2.3 billion earnings by 2029. This requires 7.8% yearly revenue growth and a roughly $0.7 billion earnings increase from $1.6 billion today.

Uncover how Cardinal Health's forecasts yield a $245.27 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community value Cardinal Health between US$190 and about US$466 per share, showing very different expectations. You can set those views against the key catalyst of rising specialty drug volumes, which sits alongside persistent regulatory and reimbursement risks that may influence how the company converts that demand into lasting earnings power.

Explore 4 other fair value estimates on Cardinal Health - why the stock might be worth 14% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Cardinal Health research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Cardinal Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cardinal Health's overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.